Coeurative

Coeurative is a private, preclinical biotech focused on a significant unmet need in cardiovascular medicine: effective treatment for angina pectoris, especially in patients with INOCA and refractory angina where current therapies fail. Its lead asset, CR-0305, employs a proprietary dual-mechanism approach that has demonstrated 23x greater vasodilatory potency than the standard-of-care isosorbide mononitrate in ex vivo studies, alongside a favorable safety profile. The company is advancing IND-enabling studies with plans to initiate Phase 1 trials in 2028, targeting a multi-billion dollar global market opportunity. Coeurative represents a high-potential, early-stage venture aiming to deliver a curative strategy for coronary artery disease.

Proprietary dual-action mechanism that harnesses a cellular response to blood/oxygen deficiency to dilate coronary arteries more effectively and selectively than current vasodilators. Demonstrated high potency and favorable safety in ex vivo and in vitro models.

Competes against established standard-of-care vasodilators (nitrates, calcium channel blockers) which are generic but have limitations like tolerance and incomplete efficacy. Also faces potential competition from other novel mechanisms in development for refractory angina and INOCA, an area of growing R&D interest. Differentiation hinges on demonstrating superior potency and a unique dual-action benefit.